Cargando…

BRCA1 Regulates Follistatin Function in Ovarian Cancer and Human Ovarian Surface Epithelial Cells

Follistatin (FST), a folliculogenesis regulating protein, is found in relatively high concentrations in female ovarian tissues. FST acts as an antagonist to Activin, which is often elevated in human ovarian carcinoma, and thus may serve as a potential target for therapeutic intervention against ovar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karve, Tejaswita M., Preet, Anju, Sneed, Rosie, Salamanca, Clara, Li, Xin, Xu, Jingwen, Kumar, Deepak, Rosen, Eliot M., Saha, Tapas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365892/ https://www.ncbi.nlm.nih.gov/pubmed/22685544 http://dx.doi.org/10.1371/journal.pone.0037697

Ejemplares similares

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

SNP analysis of follistatin gene associated with polycystic ovarian syndrome
por: Panneerselvam, Palanisamy, et al.
Publicado: (2010)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

Small Changes Huge Impact: The Role of Protein Posttranslational Modifications in Cellular Homeostasis and Disease
por: Karve, Tejaswita M., et al.
Publicado: (2011)

BRCA mutation in high grade epithelial ovarian cancers
por: Manchana, Tarinee, et al.
Publicado: (2019)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
por: Clark-Knowles, Katherine V., et al.
Publicado: (2010)

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
por: Plaskocinska, Inga, et al.
Publicado: (2016)

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions
por: Wang, Yiying, et al.
Publicado: (2017)

BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers
por: Loboda, Anna P., et al.
Publicado: (2023)

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

BRCA1 in the DNA damage response and at telomeres
por: Rosen, Eliot M.
Publicado: (2013)

BRCA1 Zinc RING Finger Domain Disruption Alters Caspase Response in Ovarian Surface Epithelial Cells
por: Johnson, Nicole C, et al.
Publicado: (2002)

Characterization of magnesium requirement of human 5'-tyrosyl DNA phosphodiesterase mediated reaction
por: Adhikari, Sanjay, et al.
Publicado: (2012)

Association of follistatin and cytochrome p450 side-chain cleavage enzyme with polycystic ovarian syndrome
por: Nazir, Fouzia, et al.
Publicado: (2022)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers
por: Ha, Hyeong In, et al.
Publicado: (2020)

BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells
por: Woolery, Kamisha T., et al.
Publicado: (2015)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
por: Barnes, Daniel R., et al.
Publicado: (2020)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Immuno-Neutralization of Follistatin Bioactivity Enhances the Developmental Potential of Ovarian Pre-hierarchical Follicles in Yangzhou Geese
por: Chen, Rong, et al.
Publicado: (2022)

Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates
por: Helpman, Limor, et al.
Publicado: (2017)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer
por: Nañez, Andrea, et al.
Publicado: (2021)

Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors
por: Janik, Stefan, et al.
Publicado: (2019)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer
por: McCoy, Marcia L, et al.
Publicado: (2003)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers
por: Sahnane, Nora, et al.
Publicado: (2023)

BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients
por: Lanjouw, Lieke, et al.
Publicado: (2023)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: Do they play a role in ovarian carcinogenesis?
por: Kim, Ki-Yon, et al.
Publicado: (2010)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Mutational Analysis of BRCA1 Gene in Ovarian and Breast‐ovarian Cancer Families in Japan
por: Takano, Masashi, et al.
Publicado: (1997)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients
por: Jarhelle, Elisabeth, et al.
Publicado: (2019)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b02dtdamjvgapa165i74krp55h